Zydus Cadila announces USFDA approval for Ibrutinib capsules
Zydus was the first ANDA applicant to submit a substantially complete ANDA with a paragraph IV certification for Ibrutinib Capsules, 70 mg.
Zydus was the first ANDA applicant to submit a substantially complete ANDA with a paragraph IV certification for Ibrutinib Capsules, 70 mg.
ranules now has a total of 38 ANDA approvals from US FDA.
The company will review FDA's response and decide on appropriate next steps soon.
It is used to treat low blood pressure that causes severe dizziness or a lightheaded feeling.
The US generic market is crucial for Indian pharma, contributing about 35% to its total revenue, around US$ 10.7 billion
The product is bioequivalent and therapeutically equivalent to the reference listed drug (RLD), VASOSTRICT Injection 40 Units per 100 mL and 20 Units per 100 mL of PH Health Limited
Dr. Reddy’s becomes the first pharmaceutical company to receive regulatory approval to launch Linaclotide in India under the brand name Colozo
KER-065 is a novel ligand trap comprised of a modified ligand-binding domain derived from activin receptor type IIA and activin receptor type IIB
Fourteenth breakthrough therapy designation granted by FDA across the oncology portfolio of Daiichi Sankyo
Subscribe To Our Newsletter & Stay Updated